Bill Enright
? After a stint consulting for Avidea Technologies, Bill Enright is back at the CEO game Vaccitech?s new chief. Like Altimmune ? which Enright led for 11 years ? Vaccitech has a dual focus on cancer and infectious diseases. The appointment… […]
Buying any late-stage drug in a biotech buyout can be fraught with danger ? and ripe for humiliation. AbbVie got a lesson on that with the final failure for Rova-T, a drug they forked over $5.8 billion in cash and equity to get its hands on.
But was th… […]
REDWOOD CITY, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Kristine Ball,… […]
SAN FRANCISCO–(BUSINESS WIRE)–#DNA–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO… […]
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that its chief financial officer, Fletcher Payne, will be stepping down from the Company to pursue another opportunity effective… […]
Morphic CEO Praveen Tipirneni has started a sideline interest that couldn?t seem more removed from drug development: drawing cartoons. […]
Three years after AbbVie Inc. bought Peter Thiel-backed Stemcentrx Inc. for as much as $5.8 billion, the Big Pharma company is killing the cancer drug at the center of the deal.
The move isn’t totally unexpected. The drug ? called rovalpituzumab, or R… […]
PALO ALTO, Calif., Aug. 29, 2019 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will par… […]
Kosaraju will add duties to his current responsibilities as chief financial officer
ALAMEDA, Calif., Aug. 29, 2019 /PRNewswire/ –?Penumbra, Inc.?(NYSE: PEN),?a global?healthcare?company?focused on innovative therapies,?today announced the promotion … […]
Made with ?Jenga chemistry,? the discovery could help crack the mystery of how high-temperature superconductors work. […]
Copyright © 2021 Biotech Networks, LLC
